PTAB
Advanced fields
2 decisions · 329msnewest first
  • PTAB · Jun 5, 2024 · IPR2024-00136 · APJ Russell E Cass · IPR · Institution

    The Board denied institution of IPR on challenged claim 1 under § 314(a), finding the Fintiv factors favored denial and the petition did not present compelling merits.

    RulingsInstitution decision
    • PTAB / AIA Trials › Discretionary denial › Fintiv (parallel litigation)Institution denied fintivInstitution denied

      “Thus, in circumstances where the Board determines that the other Fintiv factors 1–5 do not favor discretionary denial, the Board shall decline to discretionarily deny under Fintiv without reaching the compelling merits analysis. In circumstances where, however, the Board’s analysis of Fintiv factors 1–5 favors denial of institution, the Board shall then assess compelling merits. Id. at 4–5. In this case, Fintiv factors 1–5 favor denial. Specifically, weighing factors 1–5 in this case, we find that the approximately 8-month delay between the estimated trial date and the deadline for a final written decision in this IPR (factor 2), the progress of and investment made by the parties and the Court in the parallel district court case (factor 3), and the fact that Petitioner is also a party in the District Court Litigation (factor 5) outweigh Petitioner’s stipulation mitigating the concerns about overlap between the two proceedings (factor 4). Additionally, we find that factor 1 is neutral. Thus, we address whether the merits of Petitioner’s case are compelling.” slip op. at 19

    • PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)Institution denied meritsInstitution denied

      “An inter partes review may not be instituted unless it is determined that “the information presented in the petition filed under section 311 and any response filed under section 313 shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314 (2018); see also 37 C.F.R § 42.4(a) (2021) (“The Board institutes the trial on behalf of the Director.”). The reasonable likelihood standard is “a higher standard than mere notice pleading,” but “lower than the ‘preponderance’ standard to prevail in a final written decision.” Hulu, LLC v. Sound View Innovations, LLC, IPR2018-01039, Paper 29 at 13 (PTAB Dec. 20, 2019) (precedential). For the reasons provided below and based on the record before us, we determine that it is appropriate for us to exercise our discretion under 35 U.S.C. § 314(a) to deny institution in this proceeding. Accordingly, we do not institute an inter partes review based on the Petition.” slip op. at 2

    • BurdenNot shown unpatentable

      “Based on the present record, Petitioner has not presented a compelling, meritorious case that the challenged claims are unpatentable. Petitioner bases its case upon a claim construction that it ascribes to Patent Owner, and then expressly criticizes as being inconsistent with the plain and ordinary meaning of the claim language and the ’347 patent Specification. Pet. 14–15. Additionally, Petitioner does not provide reasoning or evidence showing why the applied construction is correct, and Patent Owner does not agree with the construction in the Preliminary Response. Id. Under these facts, Petitioner has failed to set forth a sufficient basis for us to find a compelling case of unpatentability. Our conclusion in this regard is consistent with the Board’s prior decisions in Hologic, Orthopediatrics, and Samsung, upon which Patent Owner relies. See Prelim. Resp. 10–14. Moreover, we find that the contrary cases upon which Petitioner relies are inapposite here because they involved alternative constructions advanced by the petitioner. For example, in 10X Genomics, the Board explained that: [E]ven if our rules and guidance were correctly interpreted as prohibiting a petitioner from relying solely on a claim construction it believes is incorrect, that is not what Petitioner has done here. Petitioner proposes alternative claim constructions and presents at least one ground of unpatentability for each construction. 10X Genomics, Paper 8 at 22 (emphasis added). Similarly, in Donnelly, also cited by Petitioner, the petition offered alternative constructions—the construction proposed by the patent owner in district court and the “proper construction” that the petitioner believed was the correct one. Donnelly, Paper 2 (Petition) at 29–33 (identifying alternative constructions of “grip portion”). For the foregoing reasons, we determine that Petitioner has not made a compelling, meritorious showing that “path parameter information,” as required by the challenged claims, is disclosed by or would have been obvious over Sesia. As a result, factor 6 does not weigh in favor of institution.” slip op. at 23

    • Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Other

      “Based on the present record, Petitioner has not presented a compelling, meritorious case that the challenged claims are unpatentable. Petitioner bases its case upon a claim construction that it ascribes to Patent Owner, and then expressly criticizes as being inconsistent with the plain and ordinary meaning of the claim language and the ’347 patent Specification. Pet. 14–15. Additionally, Petitioner does not provide reasoning or evidence showing why the applied construction is correct, and Patent Owner does not agree with the construction in the Preliminary Response. Id. Under these facts, Petitioner has failed to set forth a sufficient basis for us to find a compelling case of unpatentability. Our conclusion in this regard is consistent with the Board’s prior decisions in Hologic, Orthopediatrics, and Samsung, upon which Patent Owner relies. See Prelim. Resp. 10–14. Moreover, we find that the contrary cases upon which Petitioner relies are inapposite here because they involved alternative constructions advanced by the petitioner. For example, in 10X Genomics, the Board explained that: [E]ven if our rules and guidance were correctly interpreted as prohibiting a petitioner from relying solely on a claim construction it believes is incorrect, that is not what Petitioner has done here. Petitioner proposes alternative claim constructions and presents at least one ground of unpatentability for each construction. 10X Genomics, Paper 8 at 22 (emphasis added). Similarly, in Donnelly, also cited by Petitioner, the petition offered alternative constructions—the construction proposed by the patent owner in district court and the “proper construction” that the petitioner believed was the correct one. Donnelly, Paper 2 (Petition) at 29–33 (identifying alternative constructions of “grip portion”). For the foregoing reasons, we determine that Petitioner has not made a compelling, meritorious showing that “path parameter information,” as required by the challenged claims, is disclosed by or would have been obvious over Sesia. As a result, factor 6 does not weigh in favor of institution.” slip op. at 23

    Claim constructionDiscretionary denial
    Patents in suitUS 8,891,347
  • PTAB · Oct 8, 2021 · IPR2021-00754 · APJ Barbara A Parvis · IPR · Institution

    The Board denied institution of inter partes review of claims 1–10, 12, and 13 under § 314(a), finding the Fintiv factors favored denial because the ITC proceeding was advanced and substantially overlapped.

    RulingsInstitution decision
    • PTAB / AIA Trials › Discretionary denial › Fintiv (parallel litigation)Institution denied fintivDenied

      “The Board’s precedential decision in Fintiv sets forth the following factors the Board balances when determining whether to exercise its discretion to deny institution: 1. whether the court granted a stay or evidence exists that one may be granted if a proceeding is instituted; 2. proximity of the court’s trial date to the Board’s projected statutory deadline for a final written decision; 3. investment in the parallel proceeding by the court and the parties; 4. overlap between issues raised in the petition and in the parallel proceeding; 5. whether the petitioner and the defendant in the parallel proceeding are the same party; and 6. other circumstances that impact the Board’s exercise of discretion, including the merits. Fintiv, Paper 11 at 5–6. “[I]n evaluating the factors, the Board takes a holistic view of whether efficiency and integrity of the system are best served by denying or instituting review.” Id. at 6.” slip op. at 7

    • PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)Institution denied fintivInstitution denied

      “We determine that the merits of the Petition are not so strong as to outweigh the other Fintiv factors we consider here. Under these circumstances, we view this factor as neutral. C. Conclusion Based on the particular circumstances of this case, we determine that instituting an inter partes review is not appropriate under the standard set forth in Fintiv. As discussed above, the Final Determination in the parallel ITC proceeding is due six months before a final written decision would be due if we did institute an inter partes review, and the issues presented in this proceeding substantially overlap those issues in the parallel ITC proceeding. On balance, after a holistic consideration of the relevant facts and the particular circumstances of this case, we conclude that efficiency and integrity of the system are best served by denying institution. Thus, we exercise our discretion under § 314(a) to deny institution. IV. ORDER In consideration of the foregoing, it is hereby: ORDERED that the Petition is denied, and no trial is instituted.” slip op. at 12

    Discretionary denial
    Patents in suitUS 8,797,853

Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.